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Abstract
Background: The receptor for the peptide hormone relaxin has recently been identified as the
heptahelical G-protein coupled receptor, LGR7. In order to generate molecular tools with which
to characterize both in vivo and in vitro expression of this receptor in human and primate tissues,
specific monotypic antibodies have been generated and applied to a preliminary analysis of human
and primate female reproductive tissues.
Methods: Three peptide sequences were identified from the proposed open reading frame of the
cloned LGR7 receptor gene, representing both extracellular and intracellular domains. Two to
three rabbits were immunized for each epitope, and the resulting sera subjected to a systematic
validation using cultured cells transiently transfected with a receptor-expressing gene construct, or
appropriate control constructs.
Results: Human and monkey (marmoset, macaque) endometrium showed consistent and specific
immunostaining in the stromal cells close to glands. Staining appeared to be more intense in the
luteal phase of the cycle. Weak immunostaining was also evident in the endometrial epithelial cells
of the marmoset. A myoma in one patient exhibited strong immunostaining in the circumscribing
connective tissue. Uterine expression was supported by RT-PCR results from cultured primary
endometrial and myometrial cells. Human breast tissue (healthy and tumors) consistently indicated
specific immunostaining in the interstitial connective (stromal) tissue within the glands, but not in
epithelial or myoepithelial cells, except in some tumors, where a few epithelial and tumor cells also
showed weak epitope expression.
Conclusions: Using validated monotypic antibodies recognizing different epitopes of the LGR7
receptor, and from different immunized animals, and in different primate species, a consistent
p a t t e r n  o f  L G R 7  e x p r e s s i o n  w a s  o b s e r v e d  i n  the stromal (connective tissue) cells of the
endometrium and breast, consistent also with the known physiology of the relaxin hormone.
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Background
For many years the heterodimeric peptide hormone
relaxin was considered only as a molecule involved in the
periparturient widening of the pubic symphysis and sof-
tening of the cervix. More recently, it has been shown that
relaxin, whose structure is similar to that of insulin, is also
involved in endometrial differentiation associated with
decidualization and embryo implantation [1,2]. Relaxin
acts on primary cultures of endometrial stromal cells also
in vitro to induce the morphological and gene expression
changes, known as decidualization [1], which are the
essential prerequisite for implantation to occur. In fact,
relaxin in this context appears to be more effective even
than progesterone [1]. In addition, altered levels of circu-
lating relaxin, presumably of ovarian origin, are linked to
early embryonic loss due to implantation failure [3,4],
and it has been shown that luteinizing ovarian granulosa
cells from IVF treatments produce higher relaxin levels in
association with good pregnancy outcome [5]. Within the
female reproductive system, relaxin has also been shown
to suppress spontaneous contractions of the myometrium
in the rat [6], and to modulate uterine connective tissue
metabolism by regulating the expression of matrix metal-
loproteinases [7]. Most recently, it has also been shown to
positively influence uterine angiogenesis, probably by the
induction of local VEGF [8,9].
Relaxin is also known to be produced and have effects
within the breast [10,11]. Both H1 and H2 forms of
human relaxin have been shown to be synthesized by the
epithelial and myoepithelial cells of the human breast
[11]. Relaxin also influences growth parameters in breast
cancer cell-lines, probably using local NO pathways
[12,13], and recently, it has been shown that significantly
higher concentrations of circulating relaxin are associated
with the formation of breast cancer metastases [14]. Partly
this appears to be due to an increased ability of breast can-
cer cells to invade extracellular matrix upon relaxin stim-
ulation [15].
Two receptors responding to relaxin, LGR7 and LGR8,
were cloned and described in 2002 [16,17]. These are
novel members of the G-protein-coupled receptor super-
family, with a heptahelical transmembrane domain and a
large glycosylated ectodomain, and are distantly related to
the receptors for the glycoproteohormones, such as LH or
FSH. In transfected cell systems, these receptors are shown
to respond to relaxin by causing an elevation of intracel-
lular cAMP, presumably through a G-protein-dependent
activation of adenylate cyclase [16]. In human primary
endometrial stromal cells, a similar elevation in cAMP is
detected upon relaxin stimulation, but here inhibition of
intracellular phosphodiesterases also appears to be play-
ing an important role [18,19]. Interestingly, pharmaco-
logical studies show that for the human LGR8 both
relaxin and the recently identified peptide INSL3 (also
called relaxin-like factor, RLF) can act as effective ligands,
whereas LGR7 only responds to relaxin [17]. In rodents,
the equivalent receptors respond exclusively to either
relaxin (LGR7) or INSL3 (LGR8), with no overlap in lig-
and specificity [20]. Neither receptor is able to bind or
respond to any of the other related peptide hormones,
such as insulin, the IGF family, or the recently identifed
INSL4 [16,17,20,21]. Very recently, two further novel
receptors, GPCR135 and GPCR142, have also been char-
acterized as responding to a relaxin-like molecule, namely
relaxin 3 [22,23]. These receptors respond only very
weakly to the porcine H2 relaxin homologue and appear
not to be expressed in non-pregnant female reproductive
tissues [22,23].
Studies on receptor expression and localization in tissues
have, until now, relied upon in situ relaxin-binding, using
either radioactively labelled or biotinylated ligand [e.g.
[24-26]]. These methods mostly appear unable to yield
the sensitivity or specificity which can identify precisely
the cell types where the relaxin receptors are expressed,
and would be unable to distinguish receptors from other
proteins interacting with the hormone at high specificity
(analogous to the IGF-binding proteins). Alternatively,
primary cells can be prepared and subjected to Scatchard
analysis. Where this has been carried out, for example for
endometrial stromal cells, relaxin receptors are shown to
be expressed at a low concentration (ca. 1000 molecules
per cell), though they have a high affinity for the peptide
(Kd ~1 nM) [27].
In order to gain a better appreciation of the expression of
the LGR7 receptor protein in both normal and pathologi-
cal human tissues, we have generated a series of mono-
typic polyclonal antibodies, using as immunogens
peptides from within different regions of the human
LGR7 protein sequence. These antibodies have been sys-
tematically validated, and applied for the first time here to
human breast tissue, and human and primate uterus.
Methods and Materials
Generation of antibodies
Three different peptides were designed using the pub-
lished human LGR7 sequence as basis. Two peptides (L7-
1: CFKNYHDLQKLYLQN AND L7-2: MRKNKINHL-
NENTFAC) were derived from the large ectodomain in
regions which from preliminary folding bioinformatics
suggested the sequences to be relatively hydrophilic and
exposed on the surface of the protein, and not masked by
neighbouring glycosylations at putative Asn-X-Thr/Ser
sites. A further peptide epitope (L7-3: CSAITATEIRN-
QVKKEM) was derived from the sequence of the third
intracellular loop, in a region which has been shown to
generate good antibodies against other G-protein coupledReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/114
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receptors, for example, the oxytocin receptor [28]. All pep-
tide sequences were checked for uniqueness by searching
the international databases. The peptides were then chem-
ically synthesized and coupled via N- or C-terminal
cysteine residues to keyhole limpet hemocyanin, before
using as immunogens in rabbits, following a conven-
tional immunization protocol [29]. Peptide production
and immunization was carried out by a commercial com-
pany (Pineda Antibody Services, Berlin, Germany). All
rabbits were checked for non-specific binding of sera prior
to immunization, and pre-immune sera were collected
from all animals selected for immunization. Animals were
bled following the second boost, and these sera used for
all subsequent studies.
Cloning and transfection of human LGR7 and LGR8 
expression constructs
Full-length cDNA constructs for human LGR7 and LGR8
were kindly provided by Professor Aaron Hsueh (Stanford
University, CA). These were inserted into the pcDNA3.1-
Zeo expression vector (Invitrogen, San Diego, CA) driven
by a CMV viral promoter. In order to improve protein
expression the natural signal sequences of the two recep-
tors had been replaced by that of the human prolactin pre-
cursor polypeptide. In order to validate the specificity of
the antibodies generated, the LGR7 and LGR8 expression
constructs were transiently transfected into HEK293T
cells, using Lipofectamine 2000 (Invitrogen) according to
the manufacturer's instructions, at a DNA concentration
of 4 µg expression plasmid (encoding LGR7, LGR8 or the
orphan G-protein coupled receptor, HE6) and 0.2 µg
pEGFP-N1 (encoding enhanced green fluorescent protein;
BD Biosciences, Heidelberg, Germany) per well. Cells
were grown in 6-well plates (Nunc, Roskilde, Denmark) at
a density of 106 cells per well in DMEM with phenol red
(Sigma, Taufkirchen, Germany), 10% FCS Gold (PAA Lab-
oratories, Linz, Austria), 2 mM L-Glutamine (Gibco Pais-
ley, UK), without antibiotics. Transfection was performed
after 24 h in serum-free OPTI-MEM medium (Gibco).
After a further 24 hours, the transfected cells were seeded
into T25 flasks (Nunc), and after overnight incubation
were trypsinized, washed three times in PBS (Sigma) at
4°C, and transferred to cytospin chambers at a concentra-
tion of 50000 cells per chamber. After centrifugation at
800 rpm for 5 mins in a cytospin centrifuge, media was
removed and the cells air-dried, and then fixed in 3% (w/
v) paraformaldehyde for 10 mins, followed by 3 washes of
5 min each in PBS, and then permeabilization in 0.1% (v/
v) Triton X-100 in PBS for 5 min. After further washing
twice for 5 min in PBS, the cytospin preparations were
subjected to immunohistochemistry. In order to validate
the new antibodies generated, immune and the respective
pre-immune sera from the same animals were diluted
1:4000, and applied to the permeablized cytospin prepa-
rations. Specific immunoreactions were visualized using
the double PAP-ABC combination technique (see below)
as previously described [30], but without additional
nuclear counterstaining. As a further control, also an
expression construct encoding HE6 (generous gift from
Dr. C. Osterhoff, Hamburg, Germany), was similarly
transfected into HEK293T cells. This receptor belongs to a
discrete subfamily of heptahelical domain receptors from
LGR7, though also possesses a large glycosylated ectodo-
main [31,32]. The internal control transfections using the
EGFP expression construct all indicated a high percentage
(>60%) of cells transfected for all construct combinations
(not shown).
Immunohistochemistry of human and primate tissues
Human tissues from four patients were collected in
observance of the Helsinki Declaration, and with the
authorization of the local ethical committee. Uterine tis-
sue from two cynomolgus macaques (secretory phase)
was a generous gift from Dr UF Habenicht (Schering AG,
Berlin, Germany) and was also obtained with full ethical
approval from the appropriate authority. Marmoset mon-
key tissues (five breeding females, 3–6 years old) were col-
lected, with the approval of the local ethics commission
on animal experiments, from a breeding colony at the
German Primate Center in Göttingen, Germany, as previ-
ously described [4,33]. Tissues were immersion-fixed
overnight in buffered 10% (w/v) formaldehyde (human
tissues), in 5% buffered formaldehyde for 3 h (marmo-
sets), or in Bouin's solution overnight (macaque), before
passaging through ascending ethanols to be embedded in
paraffin. Human and macaque tissues were cut to 5–7 µm,
and processed for immunohistochemistry as previously
described [30], using the PAP(peroxidase-anti-peroxi-
dase)-ABC(avidin-biotin-complex) combination method.
Briefly, after passing through xylol and descending eth-
anols, entparafinized sections were washed 2 × 10 min in
TBS (Tris-buffered saline; 0.05 M Tris-HCl, 0.15 M NaCl,
pH 7.4), then endogenous peroxidase was suppressed by
incubation in 3% (v/v) H2O2 for 45 min at room temper-
ature (RT). Sections were then blocked with 10% (v/v)
normal goat serum for 1 h at RT. After brief rinsing in TBS,
sections were incubated with the primary antiserum,
diluted 1:4000 (L7-1, L7-2) or 1:5000 (L7-3) in antibody
dilution buffer (ADB; TBS containing 2% (v/v) normal
goat serum plus 0.05% (w/v) bovine serum albumin),
overnight at 4°C. After rinsing 3 × 5 min in TBS, sections
were then incubated with biotinylated goat-anti-rabbit
IgG, diluted 1:500 in ADB for 1 h at RT. After 3 × 5 min
rinsing in TBS, sections were then incubated in rabbit
PAP-complex (Dianova, Hamburg, Germany), again
diluted 1:500 in ADB, for 1 h at RT. After 3 × 5 min rinsing
in TBS, these last two incubation steps were repeated, this
time for only 30 min per step. After further brief rinsing in
TBS, sections were then incubated with ABC-complex
(Vector Laboratories, Burlingame, USA) for 1 h at RT.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/114
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Specific signals were detected using DAB (Sigma) as chro-
mogen, stopping the reaction by rapidly rinsing in tapwa-
ter, followed by conventional haemalaun
counterstaining. Sections were then coverslipped in aque-
ous mounting medium. Marmoset tissues used the com-
plete ABC-complex staining system (Vector Laboratories)
as recommended by the manufacturer with AEC as chro-
mogen. As controls for immunohistochemical specificity,
all sections were treated in parallel with both immune
sera and the pre-immune sera from the same animals at
the same dilutions. All immunohistochemical analyses
were completely repeated at least once for all tissues, with
identical results. As a further control, some sections were
additionally exposed to diluted primary antisera which
had been subject to a preincubation for 2 h at room tem-
perature with pure keyhole limpet hemocyanin (Sigma,
Deisenhofen, Germany) in TBS at a concentration of 10
µg/ml.
RT-PCR analysis for LGR7 gene transcripts
In order to provide some confirmatory evidence of LGR7
expression at the level of the gene transcript, a series of RT-
PCR experiments were carried out on primary cells
derived from human endometrial tissue obtained at hys-
terectomy for non-endocrine complaints. Procedures
were approved by the local ethical committee and were in
accord with the Helsinki Declaration on the scientific use
of human tissues. Primary cultures of endometrial stromal
cells and myometrial cells were prepared, as described
previously [18,34,35]. Crude glandular epithelial cells
were prepared following the enzymatic removal of stro-
mal cells, followed by differential centrifugation, essen-
tially according to the procedure of Bracken et al. [36] for
the guinea-pig. Cultures were grown in basic media (BM)
consisting of a 1:1 mixture of Ham's-F12:DMEM supple-
mented with 4 mM glutamine, 20 mM HEPES, 100 U/ml
penicillin, and 100 µg/ml streptomycin for 5–6 days until
reaching confluency. For myometrial and stromal cells,
BM was supplemented with 10% fetal calf serum (FCS)
that had been depleted of steroids by treatment with dex-
tran-coated charcoal, 1 µg/ml insulin and 10-9M 17β-
oestradiol (Sigma, Deisenhofen, Germany); for epithelial
cells 5% FCS was used. This methodology was shown to
produce stromal and epithelial cell cultures of >95%
purity based on morphology and immunohistochemisti-
cal staining for vimentin, desmin, or cytokeratin (R.T. and
Y.P, unpublished). The myometrial tissue used for cell
culture was completely free of all endometrial contamina-
tion. Where indicated, cells were incubated or not with
2.5 × 10-7M medroxyprogesterone acetate (MPA; Sigma),
or a similar concentration of progesterone (Sigma), and/
or 100 ng/ml pure porcine relaxin (courtesy Dr. O.D.
Sherwood; University of Illinois, Urbana-Champain, IL).
Cultures were submitted to differential trypsinization and
attachment for further purification and subculture before
RNA was extracted for the RT-PCR analyses using RNeasy
kits (Qiagen, Hilden, Germany) according to the manu-
facturer's instructions. For RT-PCR 5 µg total RNA was
reverse transcribed using Superscript II reverse tran-
scriptase (Invitrogen, Karlsruhe, Germany) exactly as rec-
ommended by the producer. Before each PCR reaction,
samples were denatured at 95°C for 5 min. The amplifica-
tion profile for LGR7 specific PCR reactions with primers
#176, #177, #178, #180, #181, #189 and #191 consisted
of denaturation at 94°C for 45 seconds, annealing at
54°C for 45 seconds and extension at 72°C for 2 min, fol-
lowed by a final extension for 10 min at 72°C. For the
LGR7 specific primers #174 and #178, and for GAPD
(glyceraldehyde-3-phosphate dehydrogenase) specific
primers #150 and #151 PCR conditions were modified to
denaturation at 94°C for 45 seconds, annealing at 52°C
for 1 min and extension at 72°C for 1 min. hPRL, IGF-BP1
and GAPD (primers #400, #401) transcripts were ampli-
fied according to Bartsch et al. [19]. Each reaction
included 100 pmol of each primer pair as listed in Table
1. The identity of all PCR products was confirmed by DNA
sequencing.
Results
Production and validation of polyclonal anti-LGR7 
antibodies
Polyclonal antisera were produced in rabbits against three
discrete peptide epitopes from the same polypeptide mol-
ecule which represents the principal receptor for the pep-
tide hormone relaxin, LGR7. For each epitope 2–3
different animals were immunized, each of which had
had sera checked prior to immunization for low back-
ground non-specific immunostaining. Therefore, as con-
trols for the validity of the antibodies, we are looking for
positive immunostaining which agrees in cell-type specif-
icity for all three epitopes from the same protein mole-
cule, and which further agrees between different animals
for the same epitope. As a second control system, all antis-
era are compared directly on parallel sections with the pre-
immune sera taken from the same animals and used at the
same dilution. Thirdly, it is possible that some antibodies
will be generated against the keyhole limpet hemocyanin
used as hapten, although this molecule is not expressed in
any mammalian cell. Nevertheless, there remains the pos-
sibility that such antibodies could recognize a cell-specific
mimetic epitope. In order to check for this, in further con-
trol experiments, appropriately diluted antisera were pre-
incubated with pure keyhole limpet hemocyanin to
saturate any such antibodies, before presenting them to
the tissue sections.
As principal positive control system, cytospin cultures of
transiently transfected HEC293T cells were subjected to
immunostaining under conditions identical to those used
for the tissue sections. Cells were transfected either with aReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/114
Page 5 of 13
(page number not for citation purposes)
human LGR7 expression plasmid, with an expression
plasmid encoding the closely related human LGR8 recep-
tor protein, or with a similar expression plasmid encoding
the more distantly related heptahelical receptor, HE6.
Transient transfection was deliberately used, so that
within any one field of view both transfected (immunos-
tained) and non-transfected (unstained) cells can be
directly compared. Figure 1 shows that all three LGR7
epitopes have generated specific antibodies, which only
recognize LGR7 protein (Fig. 1A,1D,1E,1F,1J,1J,1K,1L),
and not the products of the transfected LGR8 (Fig.
1B,1G,1M) or HE6 genes (Fig. 1C,1I,1N). That the trans-
fection for these gene constructs had properly functioned
was tested by using independent antibodies specific for
either LGR8 (Fig. 1H) or HE6 proteins (Fig. 1O). Similar
results, though giving differing staining intensities and
thus disclosing different antibody titers, were also
obtained for all the different rabbit sera generated from
each immunogen, whereby the L7-2 (Fig. 1D,1E,1F) and
L7-3 (Fig. 1J,1K,1L) series were markedly better than those
for L7-1.
Expression of LGR7 epitopes in primate and human 
endometrium
Tissue sections from the uterus of a cynomolgus macaque
in the secretory (luteal) phase of the estrous cycle stained
positively using all three LGR7 epitopes (Fig. 2A,2D,2G).
Staining was consistently prominent in the endometrial
stromal cells and to a varying extent also in the glandular
epithelium. The negative controls using equivalent con-
centrations of pre-immune sera were consistently
unstained (Fig. 2B,2E,2H). However, when antisera were
preincubated with keyhole limpet hemocyanin (KLH),
the epithelial staining observed in the absence of the hap-
ten (Fig. 2A,2D,2G, arrowheads) was markedly attenuated
(Fig. 2C,2F,2I), whereas the stromal staining remained
unaffected, implying that the former was likely to be due
to an unspecific staining reaction. There was only very
light and inconsistent staining in the myometrium (not
shown).
Sections of human uterus gave essentially identical results,
with prominent and specific immunostaining consist-
ently only in the stromal cell compartment of the
endometrium (Fig. 3A,3B). Negative controls using pre-
immune sera (Fig. 3C,3D) or those using a preincubation
step with KLH (not shown) indicated identical results to
those with the macaque uterus, though in the human
there was no detectable epithelial staining, even before
KLH preincubation. Of interest was that, of three patient
endometria examined, only one (Fig. 3) showed moder-
ately intense staining comparable to that of the macaque.
The other patients analysed showed only very weak or
negligble staining (not shown). The morphological
appearance of these tissues implied that these patients
were in the proliferative or early secretory phase, whereas
the positively immunostaining endometrium was from a
patient in the mid secretory phase. Of interest was the
observation, in the patient with significant LGR7 immu-
nostaining, that small fibroid nodules exhibited intense
immunoreactivity in the immediately surrounding non-
myoid tissue (Fig. 3E,3F), which was absent in sections
pretreated with the specific pre-immune serum (Fig.
3G,3H), and could not be suppressed by pre-treatment
with KLH (not shown).
For further confirmation of LGR7 gene expression in the
human uterus, RT-PCR analyses were carried out using
Table 1: Oligonucleotides used for the RT-PCR reactions.
Transcript Number Orientation Sequence Expected Size
LGR7 #174 forward 5'-TCAACACATGCCAAGACTAC-3' 522 bp
LGR7 #176 reverse 5'-GCTTCATTAACTCAGGTGGCATCT-3' (see Fig. 4C)
LGR7 #177 reverse 5'-CAAAAACACCCGGCTTCAGGA-3'
LGR7 #178 reverse 5'-TGCAGATACAACCCAGACA-3'
LGR7 #180 forward 5'-ATGACATCTGGTTCTGTCTTC-3'
LGR7 #181 reverse 5'-TCATGAATAGGAATTGAGTCTCG-3'
LGR7 #189 forward 5'-CGTGTGTGTAAAGAAGGAG-3'
LGR7 #191 forward 5'-TGTGAGCTGTATGCGATTC-3'
GAPD #150 forward 5'-TCAGCAATGCCTCCTGCAC-3' 277 bp
GAPD #151 reverse 5'-CTGCTTCACCACCTTCTTG-3'
GAPD #400 forward 5'-GCATCCTGGGCTACACTGAG-3' 140 bp
GAPD #401 reverse 5'-ACCACCTGTTGCTGTAGCC-3'
PRL forward 5'-GACAGAGACACCAAGAAGAATCGGAACATA-3' 875 bp
PRL reverse 5'-GCAATGGAACGGATCATTAAGGACCTTCTC-3'
IGF-BP1 forward 5'-TGCTGCAGAGGCAGGGAGCCC-3' 378 bp
IGF-BP1 reverse 5'-AGGGATCCTCTTCCCATTCCA-3'Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/114
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Immunohistochemical staining of cytospin preparations of HEC293T cells transfected or not with DNA constructs expressing  either LGR7, LGR8 or the orphan G-protein coupled receptor, HE6 Figure 1
Immunohistochemical staining of cytospin preparations of HEC295T cells transfected or not with DNA constructs expressing 
either LGR7, LGR8 or the orphan G-protein coupled receptor, HE6. Each panel is annotated to indicate, from left to right, the 
epitope against which the antibody has been raised (e.g. L7-2), then the animal used for this epitope (e.g. R3), and finally the 
expression construct transiently transfected into the cells (e.g. LGR7, LGR8 or HE6). All antisera against epitopes L7-1 and L7-
2 were diluted 1:4000: those against L7-3 were diluted 1:5000. Arrowheads point to positively immunostained cells. Negative 
controls are shown in panels B, C, G, H, M and N. Positive controls for the LGR8 and HE6 transfections are shown in panels H 
and O, respectively. Scale bar = 50 µm.
D) L7-2.R1/LGR7 E) L7-2.R2/LGR7 F) L7-2.R3/LGR7
G) L7-2.R2/LGR8 I) L7-2.R2/HE6
J) L7-3.R1/LGR7 K) L7-3.R2/LGR7 L) L7-3.R3/LGR7
A) L7-1.R1/LGR7
H) L8-1.R1/LGR8
B) L7-1.R1/LGR8
M) L7-3.R3/LGR8
C) L7-1.R1/HE6
N) L7-3.R3/HE6 O) HE6/HE6Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/114
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purified primary cells from endometrial stroma, epithe-
lium and myometrium of human uterine samples
obtained at hysterectomy from premenopausal patients
with non-endocrine ailments. PCR primers were so cho-
sen as to detect and distinguish both full-length LGR7
transcripts as well as the recently described [Hsu et al.,
2002] splice variant. The results show that only a single
LGR7 transcript is detectable in endometrial stromal cells,
epithelial cells and myometrial cells (Fig. 4). Because
these cells were cultured for several days, it is not possible
to state whether the apparent differences in amounts are
due to real differences in expression in vivo. However, it is
clear from this experiment that the cycle-dependent effec-
tors progesterone and relaxin have no effect in vitro on the
level of LGR7 transcript expression (Fig. 4A). Similar
results were obtained using endometrial stromal cells
under conditions known to promote decidualization in
vitro, as evidenced by the induction of transcripts for pro-
lactin (PRL) and IGF-binding protein 1 (IGF-BP1) (Fig.
4B). None of the effector combinations used, which
included relaxin, progesterone and the specific phos-
phodiesterase 4 inhibitor, rolipram (Bartsch et al., 2004),
had any influence on LGR7 transcript levels in these cells
(Fig. 4B). Also direct application of the second messenger
8Br-cAMP failed to affect LGR7 transcript level. A more
detailed analysis of the LGR7 transcripts expressed in the
human endometrial stromal cells (Fig. 4C), using various
Immunostaining of sections of uterus (endometrium) from a  single female cynomolgus macaque in the secretory phase of  the estrous cycle Figure 2
Immunostaining of sections of uterus (endometrium) from a 
single female cynomolgus macaque in the secretory phase of 
the estrous cycle. Specific LGR7 immunostaining is consist-
ently observed in endometrial stromal cells for all three 
LGR7 epitopes (A, L7-1; D, L7-2; G, L7-3), which is not 
observed when applying the preimmune sera at the same 
concentration (B, E, H). Variable immunostaining is observed 
also in the glandular epithelial cells (A, D, G; arrowheads, 
which, however, is completely attenuated upon preincubating 
the diluted primary antisera with an excess of the hapten, 
KLH (C, F, I). Sera from only one animal was chosen for each 
epitope (L7-1, R1; L7-2, R2; L7-3, R3). A second monkey, 
also in the secretory phase, was also analysed in parallel with 
identical results (not shown). Scale bar = 50 µm.
L7-1 L7-1 L7-1
L7-2 L7-2 L7-2
L7-3 L7-3 L7-3
immune serum preimmune serum KLH-blocked
A. B. C.
D. E. F.
G. H. I.
Immunostaining of human uterus using antisera recognizing  the L7-2 (R2) and L7-3 (R3) epitopes (A, B) Figure 3
Immunostaining of human uterus using antisera recognizing 
the L7-2 (R2) and L7-3 (R3) epitopes (A, B). Only a single 
patient in the mid-late secretory phase, is illustrated, since of 
other tissues examined from four other patients of the pro-
liferative or early secretory phase, none showed consistent 
immunostaining (see text). This patient also exhibited small 
fibroid nodules (E, F) in the myometrium, which immunos-
tained strongly and specifically for both LGR7 epitopes 
tested. The respective pre-immune sera from the same ani-
mals and at the same dilution as used for the primary anti-
bodies, served as negative controls (C, D, G, H). Scale bar = 
50 µm.
A. B.
C. D.
E. F.
G. H.
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combinations of oligonucleotide primers covering most
of the published transcript sequence, showed that even
small transcript variants, such as could occur by alterna-
tive splicing of the several small exons in the region
encoding the ectodomain, do not appear to be expressed
in detectable quantities in these cells. Moreover, these
PCR products were excised from the gels, sequenced and
shown to be exactly as predicted from the published full-
length LGR7 cDNA sequence [16].
Finally, uterine tissues from marmoset monkeys at known
days within the estrous cycle, or within pregnancy were
assessed using all three L7-1, L7-2 and L7-3 recognizing
antisera. Figure 5 illustrates the results using the L7-1
antisera. The other sera gave identical images (not
shown). Just as for the other primate species, specific
immunoreactive signals were most evident in the stromal
cells, particularly those close to glandular elements. Signal
intensity was generally weak during the follicular phase
(Fig. 5A,5B), though increased under the gonadotropin
surge (Fig. 5C). Staining increased progressively through
the luteal phase (Fig. 5D,5E,5F), and declined in intensity
at the end of the luteal phase where no pregnancy had
occurred (Fig. 5G). Besides the marked stromal cell stain-
ing, there is also clear epithelial immunostaining in some
sections (e.g. Fig. 5A), which is not present in the negative
controls (Fig. 5H,5I), and cannot be suppressed by prein-
cubating the antisera with KLH (not shown).
Expression of LGR7 epitopes in normal and cancerous 
human breast tissues
Similar procedures were also carried out on normal lactat-
ing human breast tissue (Fig. 6), and on breast tissue
containing tumors of various degrees of development and
differentiation (Fig. 6). In the healthy breast tissue, and
for most of the tumors examined, only the stromal com-
partment showed consistent and specific immunostaining
of a similar character using the two most immunogenic
LGR7 epitopes, L7-2 and L7-3. Staining is particularly
marked in those regions of the stromal mesenchyme adja-
cent to glandular epithelia. In the healthy tissue the glan-
dular and myoepithelium are consistently free of
immunostaining. For the tumors a very similar picture is
seen, also similar for the epitopes, L7-2 and L7-3 (Fig. 7).
In occasional regions of the sections including breast
tumor tissue, also some specific staining can be detected
in epithelial-derived tumor cells (Fig. 6M,6N,6P,6R and
6S; arrowheads). Immunostaining is unaffected by pre-
treatment with the KLH hapten (Fig. 7).
Discussion
Antibodies represent one of the most sensitive instru-
ments for the detection of receptor proteins in situ in tis-
sue sections, and offer a high spatial resolution by
comparison with radiolabelled ligand-binding or in situ
mRNA hybridization. The use of biotinylated ligands can
also offer a high resolution, but may be accompanied by
problems of non-specific binding. In a recent study where
biotinylated relaxin was used to detect binding proteins
and possibly receptors in the marmoset uterus, a method
was employed which also indicated the electrophoretic
mobility of the binding moieties [26]. Although some of
the proteins detected might have represented receptors,
other proteins of a diverse range of molecular weights
were also observed, reinforcing the limited specificity of
such methodology. We have made similar observations
also for the human uterus (Y. Pohnke, unpublished obser-
vations). In the present study, polyclonal antibodies were
raised against three quite different epitopes of the recently
cloned LGR7 heptahelical domain relaxin receptor. For
each epitope two or three rabbits had been immunized.
Thus, as a first criterion of specificity, only those immu-
nostaining features common to all three epitopes, and for
more than one animal per epitope, can be considered as
specific for the relaxin receptor. As a second criterion, all
immunostaining was perfomed in parallel using as nega-
tive controls pre-immune sera from the same animals and
at the same dilutions, under which conditions only the
specific signals should not be detected. Thirdly, since all
peptide epitopes were cross-linked to keyhole limpet
hemocyanin (KLH) as a common hapten, it is possible
that false positive immunostaining, meeting the above
two criteria, could be obtained when antibodies recogniz-
ing the KLH cross-react with a mimetic epitope of some
kind, though considerable experience of many scientists
over the years suggests that this is a very unusual event for
this hapten. To check for such source of error, antibodies
were additionally pre-incubated with a large excess of
pure KLH prior to applying them to tissue sections. The
results showed that for the uterine sections of the
cynomolgus macaque the staining in the epithelial cell
layer may have been due to such false positive reactions.
In contrast, the staining of the endometrial stroma
remained quantitatively unaltered. In the human
endometrium there was no such epithelial staining in the
first place, reinforcing the view that, where this occurred
in the macaque, this was indeed probably due to a false
positive reaction. Finally, as positive controls, cytospin
preparations were made of cell-lines having no
endogenous relaxin receptors, as well as of similar cells
transiently transfected with expression constructs encod-
ing the LGR7 receptor, or alternatively the related recep-
tors, LGR8 and HE6. All the LGR7 antibodies used
showed clear positive staining only in those cells trans-
fected by the LGR7 constructs, and neither in non-trans-
fected cells nor in the cells expressing the other related
receptors. In an independent study in the rat brain, the
antibodies L7-2 and L7-3, whose immunogenic epitopes
differ only slightly between humans and rats, indicate
complete cellular identity between immunostaining, 33P-Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/114
Page 9 of 13
(page number not for citation purposes)
RT-PCR reactions for LGR7 gene transcripts in human uterine cells Figure 4
RT-PCR reactions for LGR7 gene transcripts in human uterine cells. A. Primary cultures of endometrium stromal cells (ESC), 
glandular epithelial cells (EPI) and myometrial smooth muscle cells (MYO) cultivated for 6 days and treated or not, as indicated 
with 2.5 × 107M medroxyprogesterone acetate (MPA) and/or 100 ng/ml porcine relaxin. The LGR7 PCR used primers #174 
and #178, that for GAPD used #150 and #151. B. Primary cultures of endometrial stromal cells cultured for 3 or 6 days as 
indicated with progesterone (prog., 2.5 × 10-7M), relaxin (100 ng/ml), rolipram (ro., 100 µM) and their combinations. RT-PCR 
products for prolactin (PRL), IGF-BP1 and GAPD mRNAs were performed in parallel on 6 day cultures only. All lanes are from 
the same gels run and photographed under identical conditions; the images have been cut to eliminate unwanted tracks only. 
PCR primers for LGR7 were as above, for GAPD #400 and #401 were used. C. RT-PCR reactions for RNA from a single 
preparation of ESC cells using different primer conditions (see lower panel) in order to determine the expression of possible 
LGR7 splice variants. The sizes of the DNA markers are indicated on the left of the upper panel. In the lower panel the sizes of 
the expected products, based on the published cDNA sequence, are indicated above the horizontal arrows. Primer #180 is 
positioned to include the start codon of the open reading frame, whereas #189 and #190 are both within the 5' untranslated 
region.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/114
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relaxin binding and in situ mRNA hybridization (T.
Burazin, University of Melbourne, personal communica-
tion). Given these extensive controls, we can be confident
that the immunostaining seen truly represents the relaxin
receptor LGR7.
Within the uterus, marked specific immunostaining is
seen in the endometrial stromal cells in human, macaque
and marmoset uterus. The stroma is not uniformly stained
but in patches within the functionalis but not in the basalis.
Staining appears to be strongest in those stromal cells
adjacent to, or circumscribing endometrial glands. The
marmoset monkey offers an ideal model in which to
study this expression, since tissues can be obtained from
animals whose cycles are precisely synchronized by a lute-
olytic dose of prostaglandin-F2α [33], and hence at pre-
cise days of the cycle or pregnancy. Using such tissues, and
in an independent laboratory, LGR7-immunostaining
was observed essentially identical to that observed for the
other species, with most being in the stromal cells close to
endometrial glands. In the marmoset we can confirm the
suggestion offered by the human tissues, that LGR7
immunoreactivity increases from the proliferative to the
luteal pase of the cycle. It increases still further in early
pregnancy, concomitant with a role in the decidualization
process essential for implantation (not shown). The mar-
moset results were also fully coherent with the results of
biotinylated-RLX binding [26], acting as a further control
for the validity of the antibodies in these species.
The epithelial staining, observed consistently for some
antibodies in the macaque, is attenuated by preincubaton
of the antibodies with an excess of KLH and therefore
probably represents unspecific false positive immunos-
taining. The weak but specific epithelial staining seen in
the marmoset monkey appears to be truly specific and is
Immunostaining for LGR7 epitopes (L7-1) in the  endometrium of the marmoset monkey Figure 5
Immunostaining for LGR7 epitopes (L7-1) in the 
endometrium of the marmoset monkey. A, day 4 follicle 
phase. B, day 7 follicle phase. C, day 8 follicle phase, following 
administration of a single ovulatory dose of hCG. D, From 
another animal as in C, showing a larger overview. E, day 3/4 
of the luteal phase, overview. F, As in E, detail. G, day 9 luteal 
phase. H, negative control using preimune serum: day 8/9 of 
the follicle phase after application of hCG. I, negative control, 
day 3/4 of the luteal phase. Scale bars in all figures represent 
50 µm.
A B C
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Immunostaining for LGR7 epitopes of healthy human breast  tissue from a lactating patient, undergoing mammotomy for  incipient breast cancer Figure 6
Immunostaining for LGR7 epitopes of healthy human breast 
tissue from a lactating patient, undergoing mammotomy for 
incipient breast cancer. This tissue has been described else-
where [42]. Antibodies against the epitopes L7-2 (panels A 
and C) and L7-3 (panels B and D) were used, and gave identi-
cal results (L7-2.R2 was used at 1:4000, and L7-3.R3 at 
1:5000 dilution). The effect of preincubating the antibodies 
with an excess of KLH was also tested: A and B, without 
KLH; C and D, with KLH. The preimmune sera from the 
same animals used to generate the specific antisera were 
applied in E and F, at the same dilutions. Scale bar = 50 µm.
A. B.
C. D.
E. F.
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not attenuated in KLH-suppression controls. Negligble
immunostaining was observed in the myometrium in all
three species. This may be due to true low level expression
of the LGR7 receptor protein, though may represent a
methodological problem; other receptor proteins in our
hands have sometimes required a microwave antigen-
retrieval protocol to be visualized in this tissue (MB, per-
sonal observations).
These observations of LGR7 immunoexpression in the
uterus are very much in agreement with studies using puri-
fied human primary cell cultures. Relaxin has been shown
to have an important effect in the induction of deciduali-
zation in endometrial stromal cells [1,37]. This effect is
mediated by well characterized relaxin receptors on the
cell surface, expressed at a concentration of ca. 1000 mol-
ecules per cell, and having a Kd of ≤ 1 nM [24]. Relaxin is
also known to influence myometrial function by inhibit-
ing spontaneous contractions, though these effects are
most marked in rodents, and are considered not signifi-
cant in the human [38]. Relaxin-binding is also reported
for endometrial epithelial cells [25], and functional
responses to relaxin have been reported also for these cells
[9,39,40].
Using RT-PCR we can detect LGR7 mRNA in all three uter-
ine cell types. Since these are cultured cells, however, these
experiments cannot provide information about the levels
of transcripts or protein in the intact tissues. Furthermore,
the relative levels might be distorted by the proportion of
cells expressing the LGR7 transcripts. The immunohisto-
chemistry emphasizes that not all stromal cells express
LGR7, but only some of them, and this probably in a
cycle-dependent manner. Depending on the ratio of
expressing to non-expressing cells in the primary cultures,
the observed mRNA concentrations in the extracted RNA
samples could vary greatly. What is significant, however,
is that known uterine effectors, like progesterone and
relaxin, have no effect on the LGR7 gene expression in
these cultured cells. This would imply that any cycle-
dependent variation in vivo requires a more complex col-
lection of factors and/or paracrine interactions. Tran-
scripts for the shorter splice variant do not appear to be
expressed in the cultured cells to any significant degree.
Thus, although potentially this transcript could give rise to
a free ectodomain, which has experimentally been shown
to bind relaxin [16], there is still no evidence that such
splice variants are expressed or translated in vivo, or that
any such free ectodomain is exported from the cells.
Of particular interest, was the observation in one patient
of fibroid nodules in the myometrium, which were clearly
enveloped by positively immunostaining connective tis-
sue cells. While this is possibly part of the normal encap-
sulation response towards such fibroids, it provokes the
question of what role relaxin and its receptor could be
playing in the etiology and pathology of this debilitating
ailment.
In the normal and pathological human breast, LGR7
immunoreactivity is prominent in the stromal connective
tissue between the glandular lobules. Epithelial cells of
the healthy breast are unstained. Such epithelial staining
does appear to occur sporadically in breast tumor tissue,
Immunohistochemistry of primary breast tumors from four  different patients Figure 7
Immunohistochemistry of primary breast tumors from four 
different patients. A-E: ER- and PR-positive lobular breast 
tumor, grade 2. F-J: ER- and PR-positive ductal breast tumor, 
grade 1. K-O: ductal breast cancer, also ER- and PR-positive, 
grade 1. P-T: ductal tumor, ER- and PR-positive, grade 2. As 
in Fig. 5, all tumors are stained for both L7-2 (A, F, K.P) and 
L7-3 (C, H, M, R) epitopes in the absence of KLH preincuba-
tion, or in its presence (B, D, G, I, L, N, Q, S). Negative con-
trols for both epitopes are also shown (E, T: preimmune 
serum for L7-2.R2; J, O: preimmune serum for L7-3.R3). 
Other controls were similar (not shown). Note that the 
weak, but specific immunostaining of the epithelial tumor 
cells (e.g. in M and R; arrowheads and elsewhere) was not 
suppressed by preincubation of the primary antisera with 
KLH. Scale bar = 50 µm.
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which would be in agreement with the findings that the
breast cancer cell-line MCF7, believed to be of epithelial
origin, is also responsive towards relaxin [12]. While the
tumor tissue is mostly unstained, in some tumors weak
and localized staining can be observed. Several studies
have looked at a role for relaxin in human breast function,
particularly in the context of cancer [11,13]. It is reported
that breast cancer cell lines can respond to relaxin by a
change in growth parameters, probably involving local
NO production [41]. More interestingly, it has recently
been shown that women with metastatic breast cancer
have significantly higher serum relaxin concentrations
than those with non-progressing cancer [14]. Further-
more, breast cancer cells treated with relaxin show a sig-
nificant increase in invasive potential, using a classic in
vitro invasion assay [15]. These studies thus emphasize the
importance of relaxin on connective tissue remodelling in
the breast particularly in relation to cancer progression
and metastasis formation, and support well our
observations using the new LGR7 antibodies that the
relaxin receptor is prominently expressed on the connec-
tive tissue cells responsible for creating a capsule around a
growing tumor, as well as on some tumor cells of epithe-
lial origin in breast cancer patients. The similarity here to
the situation for the uterine fibroids is striking.
The present article describes a new panel of polyclonal
antibodies generated against the human LGR7 receptor.
Using a combination of immunochemical, molecular bio-
logical and immunohistochemical techniques we here
provide a first validation of these antibodies and
demonstrate their value in studying the physiology and
pathology of the human breast and uterus.
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